Norman E. Sharpless MD was trained in internal medicine at the Massachusetts General Hospital, and hematology and oncology at the Dana-Farber Cancer Institute, both at Harvard Medical School. He is currently the Director of the National Cancer Institute; previously he served as the Wellcome Distinguished Professor of Cancer Research at the University of North Carolina at Chapel Hill, as well as the Director of the Lineberger Comprehensive Cancer Center. He has authored more than 100 papers and book chapters as well as 10 patents on the molecular biology of cancer and aging. His research lab discovered the beneficial effects of Pharmacological Quiescence (PQ™) with regard to protection from DNA damaging agents. He is on the scientific advisory board of several scientific foundations, is Deputy Editor of the Journal of Clinical Investigation and serves as an elected council member of the American Society of Clinical Investigation, the nation’s oldest honor society for physician-scientists.
Natalia Mitin, PhD has over 15 years of experience in various research areas of life sciences. She has a strong background in molecular biology, biochemistry and cellular biology. In the last 10 years, Dr. Mitin held a research faculty position in the Department of Pharmacology at UNC Chapel Hill. During her tenure at UNC, Dr. Mitin trained and supervised research personnel, set up and managed collaborations, and procured funding. After leaving UNC, Natalia joined HealthSpan Dx where she led all assay development efforts and clinical collaborations, solicited non-dilutive funding, and managed day to day operations and business development opportunities.
Mr. Romanowsky has over 20 years of healthcare strategy and commercialization experience, including nearly 15 years focused on launching and promoting novel molecular diagnostics based on RNA expression profiling. He has lead marketing, reimbursement, sales and commercial teams for CardioDx and CareDx, Veracyte, Telomere Diagnostics, and Inflammatix. At CareDx, Mr Romanowsky led product development and commercialization efforts for AlloMap, the only FDA-approved RNA expression diagnostic available in the cardiovascular space. Mr Romanowsky has been an advisor to HealthSpan Diagnostics in the last year and will lead HealthSpan Diagnostic’s comprehensive commercialization strategy, with special focus on positioning the product based on clinical performance and utility, as well leading pricing and reimbursement strategy, and marketing and education campaigns.
Dr. Elam has over 20 years of experience in entrepreneurship research and practice across a number of different industries. She is President and co-founder of a molecular diagnostics firm located in the RTP, Galaxy Diagnostics, and holds a research appointment in entrepreneurship, innovation, and women leadership at Babson College. Dr Elam has been advising HealthSpan Diagnostics since the company was founded on various aspects of business development and growth, operational considerations, and fundraising.